论文部分内容阅读
【目的】探讨中药复方心脉通胶囊对缺血性心脏病的治疗作用及其作用机制。【方法】 6 0例冠心病心肌缺血患者随机分为心脉通胶囊组 (30例 ,常规西药加心脉通胶囊治疗 )与对照组 (30例 ,单用常规西药治疗 ) ,观察治疗前后临床症状计分、心肌缺血总负荷 (TIB)、血浆内皮素 (ET)、一氧化氮 (NO)和血清超氧化物歧化酶 (SOD)、丙二醛 (MDA)的变化。【结果】治疗后两组临床症状计分、TIB、MDA均显著下降 (P <0 .0 5 ) ,而心脉通胶囊组下降幅度明显大于对照组 (P <0 .0 1) ,心脉通组ET显著下降 (P <0 .0 1) ,但对照组下降不明显 (P >0 .0 5 ) ;两组治疗后NO、SOD明显上升 (P <0 .0 5 ) ,而心脉通组上升幅度显著高于对照组 (P <0 .0 1)。【结论】心脉通胶囊有良好抗心肌缺血作用 ,其作用机制与血管内皮保护效应及抗脂质过氧化损伤密切相关 ,加用心脉通胶囊治疗缺血性心脏病比单用西药效果好。
【Objective】 To investigate the therapeutic effect of Xinmaitong Capsule on ischemic heart disease and its mechanism. 【Methods】 Sixty patients with coronary heart disease were randomly divided into two groups: Xinmaitong capsule group (30 cases, conventional western medicine plus Xinmaitong capsule) and control group (30 cases, treated with conventional western medicine alone). Clinical symptom scores, total myocardial ischaemia (TIB), plasma endothelin (ET), nitric oxide (NO) and serum superoxide dismutase (SOD), malondialdehyde (MDA) changes. 【Results】 After treatment, the scores of clinical symptoms, TIB and MDA were significantly decreased in the two groups (P < 0.05), while the decline in Xinmaitong Capsule group was significantly greater than that in the control group (P <0. 01). ET decreased significantly in the group (P < 0.01), but there was no significant decrease in the control group (P> 0.05); NO and SOD increased significantly after treatment in both groups (P <0.05). The rise of Tongtong group was significantly higher than that of the control group (P < 0.01). 【Conclusion】Xinmaitong capsule has good anti-ischemic effect on myocardium, and its mechanism of action is closely related to the protective effect of vascular endothelium and anti-lipid peroxidative injury. The addition of Xinmaitong Capsule for treating ischemic heart disease is more effective than western medicine alone. .